David Kavanagh1, Timothy H J Goodship. 1. The Institute of Human Genetics, International Centre for Life, Newcastle University, Newcastle upon Tyne, UK. david.kavanagh@ncl.ac.uk
Abstract
PURPOSE OF REVIEW: The last few years revealed a molecular distinction between thrombotic thrombocytopenic purpura, a disease characterized by a lack of ADAMTS13 activity, and atypical hemolytic uremic syndrome (aHUS), a disease of complement overactivation. Many different predisposing genetic factors resulting in complement overactivation have been described in aHUS. Additionally, autoantibodies against complement regulatory proteins have been reported. RECENT FINDINGS: The last year has seen the description of a new risk factor for aHUS in the form of mutations in thrombomodulin. As with other genetic risk factors seen in aHUS, these mutations result in impaired regulation of complement. It is increasingly recognized that a confluence of risk factors resulting in complement overactivation may be required for the disease to manifest. In the last year the complement inhibitor eculizumab has been used successfully to treat patients with aHUS. SUMMARY: The characterization of the molecular defect in aHUS has allowed targeted therapy to be used. Although early reports of the efficacy of the complement inhibitor eculizumab are promising, the outcome of a recent clinical trial is awaited.
PURPOSE OF REVIEW: The last few years revealed a molecular distinction between thrombotic thrombocytopenic purpura, a disease characterized by a lack of ADAMTS13 activity, and atypical hemolytic uremic syndrome (aHUS), a disease of complement overactivation. Many different predisposing genetic factors resulting in complement overactivation have been described in aHUS. Additionally, autoantibodies against complement regulatory proteins have been reported. RECENT FINDINGS: The last year has seen the description of a new risk factor for aHUS in the form of mutations in thrombomodulin. As with other genetic risk factors seen in aHUS, these mutations result in impaired regulation of complement. It is increasingly recognized that a confluence of risk factors resulting in complement overactivation may be required for the disease to manifest. In the last year the complement inhibitor eculizumab has been used successfully to treat patients with aHUS. SUMMARY: The characterization of the molecular defect in aHUS has allowed targeted therapy to be used. Although early reports of the efficacy of the complement inhibitor eculizumab are promising, the outcome of a recent clinical trial is awaited.
Authors: Tommi Kajander; Markus J Lehtinen; Satu Hyvärinen; Arnab Bhattacharjee; Elisa Leung; David E Isenman; Seppo Meri; Adrian Goldman; T Sakari Jokiranta Journal: Proc Natl Acad Sci U S A Date: 2011-02-01 Impact factor: 11.205
Authors: Sally Johnson; Jelena Stojanovic; Gema Ariceta; Martin Bitzan; Nesrin Besbas; Michelle Frieling; Diana Karpman; Daniel Landau; Craig Langman; Christoph Licht; Carmine Pecoraro; Magdalena Riedl; Ekaterini Siomou; Nicole van de Kar; Johan Vande Walle; Chantal Loirat; C Mark Taylor Journal: Pediatr Nephrol Date: 2014-05-11 Impact factor: 3.714
Authors: E B Volokhina; D Westra; T J A M van der Velden; N C A J van de Kar; T E Mollnes; L P van den Heuvel Journal: Clin Exp Immunol Date: 2015-08 Impact factor: 4.330
Authors: Elisabetta Valoti; Marta Alberti; Agustin Tortajada; Jesus Garcia-Fernandez; Sara Gastoldi; Luca Besso; Elena Bresin; Giuseppe Remuzzi; Santiago Rodriguez de Cordoba; Marina Noris Journal: J Am Soc Nephrol Date: 2014-06-05 Impact factor: 10.121
Authors: Elena Volokhina; Dineke Westra; Xiaoguang Xue; Piet Gros; Nicole van de Kar; Lambert van den Heuvel Journal: Pediatr Nephrol Date: 2012-06-06 Impact factor: 3.714